HiLung Inc. is pleased to announce that Toshio Suzuki, Director / Head of Translational Science, will deliver an oral presentation at the 53rd Annual Meeting of the Japanese Society of Toxicology, to be held from July 1 to 3, 2026, at Grand Cube Osaka (Osaka International Convention Center) in Osaka, Japan.
Dr. Suzuki will present research on a human-predictive platform for drug-induced lung injury assessment using human iPSC-derived alveolar organoids during Oral Session 7: Respiratory System on Friday, July 3.

Drug-induced lung injury is a serious adverse event that can constrain the development of a wide range of therapeutic agents, including anticancer drugs. However, conventional animal models and two-dimensional cell culture systems do not fully reproduce the human alveolar microenvironment or its complex cellular interactions.
In this presentation, HiLung will introduce an alveolar organoid platform composed of human iPSC-derived alveolar epithelial cells and human lung fibroblasts for evaluating drug-induced lung injury. The study also incorporates co-culture with human iPSC-derived tissue-resident alveolar macrophages to examine how immune components influence drug-induced injury, inflammatory responses, and tissue repair.
The platform enables multidimensional assessment of organoid contraction, structural disruption, epithelial injury, inflammation-related responses, and fibrosis-associated phenotypes. Single-cell RNA sequencing is further used to evaluate cellular state transitions and disease-associated signaling in fibrogenic drug-induced lung injury models.
Through the development and application of human iPSC-derived lung models, HiLung aims to advance human-relevant safety assessment technologies and support more predictive drug discovery and respiratory safety evaluation.
For further information on the meeting, please visit the official website: